Technetium-99m labeled p-aminohippuric acid analogues: renal function agents

Area of Science:

• Nuclear medicine
• Radiopharmaceutical chemistry
• Renal physiology

Background:

• P-aminohippuric acid (PAH) derivatives are crucial for renal function assessment.
• Developing stable 99mTc-labeled radiopharmaceuticals offers advantages for imaging and diagnostics.
• Current methods like [131I]o-iodohippuric acid require evaluation for potential replacement.

Purpose of the Study:

• To synthesize and evaluate novel p-aminohippuric acid analogues as 99mTc-labeled radiopharmaceuticals.
• To assess the stability and biodistribution of these new complexes for renal function imaging.
• To identify potential candidates for improved clinical evaluation of kidney function.

Main Methods:

• Synthesis of various p-aminohippuric acid analogues.
• Formation of stable 99mTc-labeled complexes using a Sn(II) reduction method at pH 5.7.
• In vivo screening through biodistribution studies in small animal models.
• Assessment of excretion pathways and organ uptake post-intravenous administration.

Main Results:

• All synthesized analogues formed stable 99mTc complexes.
• Biodistribution studies showed rapid excretion via the genitourinary (GU) tract within 60 minutes.
• No significant accumulation was observed in the gastrointestinal tract or liver.
• The [99mTc]methyl-PAHIDA complex exhibited optimal biodistribution characteristics among the tested analogues.

Conclusions:

• Novel 99mTc-labeled p-aminohippuric acid analogues were successfully synthesized and characterized.
• The [99mTc]methyl-PAHIDA complex shows favorable biodistribution for potential use in renal function evaluation.
• Further research is warranted to determine if these agents can replace [131I]o-iodohippuric acid in clinical settings.